Heidi Wang

Dr. Heidi Wang received her Ph.D. from University of Notre Dame in Indiana, USA. She is the Vice President and Head of Global Regulatory Science-China and Hong Kong, Bristol-Myers Squibb Company (BMS). She has led the teams to obtain three first-in-class drug approvals in China, including HCV direct acting agents (Daklinza and Sunvepra) and an Immuno-Oncology PD-1 inhibitor (Opdivo). Prior to China, Dr. Wang had over 20 years of experience working in BMS US headquarter with responsibilities in the US and 38 other countries.